About OMICS International - .About OMICS International OMICS International through its Open Access

  • View
    217

  • Download
    0

Embed Size (px)

Text of About OMICS International - .About OMICS International OMICS International through its Open Access

  • About OMICS International OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700 leading-edge peer-reviewed Open Access Journals and organizes over 1000+ International Conferences annually all over the world. OMICS International journals have over 3 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 50000 About OMICS International eminent personalities that ensure a rapid, quality and quick review process. OMICS International signed an agreement with more than 1000 International Societies to make healthcare information Open Access. OMICS International Conferences make the perfect platform for global networking as it brings together renowned speakers and scientists across the globe to a most exciting and memorable scientific event filled with much enlightening interactive sessions, world class exhibitions and poster presentations. www.conferenceseries.com

  • Proteomic Strategies to overcome Tumor Resistance to Oncology Targeted Medicines

    Extending development and treatment options through

    precise molecular profiling

    Chee Gee See, PhD, MICR, Director of Personalised Medicine, Proteome Sciences plc, Coveham House, Cobham, Surrey UK.

    www.proteomics.com 2

    6th International Conference on Biomarkers and Clinical Research, Toronto, Canada.

    1st September 2015

    http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/

  • http://www.fda.gov/downloads/scienceresearch/specialtopics/personalizedmedicine/ucm372421.pdf

    http://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-time

    Nature Review Drug Discovery 11, 201-214 (20

    www.proteomics.com 3

    12)

    Personalised medicine is often

    described as providing the

    right patient with the right drug at the right dose at the right time .

    Personalised Medicine

    http://www.fda.gov/downloads/scienceresearch/specialtopics/personalizedmedicine/ucm372421.pdfhttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.astrazeneca.com/About-Us/Features/Article/20100311--Right-patient-right-drug-right-timehttp://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/

  • Drug

    Maker

    Personalised

    Medicine

    Indication

    Diagnostic Biomarker

    Biomarker

    Frequency in

    Population

    Overall

    Response

    Rate

    Median

    Time To

    Progression

    Roche Herceptin mBC & EBC HER2 overexpression 20% 15% 9.1 mths 1

    Roche Herceptin mGC & mGEJC HER2 overexpression 20% 47.3% 7.6 mths 2

    GSK Tykerb mBC HER2 overexp / EGFR 20% 22% 8.4 mths 3

    AstraZeneca

    Iressa

    NSCLC

    EGFR mutation

    10 % ( 30-50%)

    71.2%

    8.35 mths 4

    Roche Tarceva NSCLC EGFR mutation 10 % ( 30-50%) 65% 10.4 mths 5

    Pfizer Xalkori NSCLC ALK-EML4 FISH 3-6% 50-61% 5.5 8 mths 6

    Amgen Vectibix mCRC kRAS wt 50% 55% 9.6 mths 7

    BMS Erbitux mCRC kRAS wt 50% 57% 9.5 mths 8

    Roche Zelboraf Melanoma BRAF V600E mutation 50-90% 52% 6.5 mths 9

    1). Cobleigh et al 1999. J Clin Oncol. 17:2639-2648. 2). NICE appraisal guidance document 208 3). Tevaarwek & Kolesar 2009. Clin Ther 31, 2332 2348. 4). Mok et al 2009. N Engl J Med ;361:94757. 5). EURTAC study 6). PROFILE 1005 (PhII) & 1001 (PhI) studies 7).PRIME trial, FDA approval.. 8). CRYSTAL trial, FDA approval 9). FDA approval note for Vemurafenib.

    www.proteomics.com 4

    Personalised Medicine

    http://www.nice.org.uk/nicemedia/live/13275/51681/51681.pdfhttp://www.nice.org.uk/nicemedia/live/13275/51681/51681.pdfhttp://www.nice.org.uk/nicemedia/live/13275/51681/51681.pdfhttp://www.tarceva.com/hcp/nsclc/first-line-efficacy-and-safety#orrhttp://www.tarceva.com/hcp/nsclc/first-line-efficacy-and-safety#orrhttp://www.pfizer.com/sites/default/files/news/asco/xalkori_fact_sheet.pdfhttp://www.pfizer.com/sites/default/files/news/asco/xalkori_fact_sheet.pdfhttp://www.pfizer.com/sites/default/files/news/asco/xalkori_fact_sheet.pdfhttp://www.pfizer.com/sites/default/files/news/asco/xalkori_fact_sheet.pdfhttp://www.pfizer.com/sites/default/files/news/asco/xalkori_fact_sheet.pdfhttp://www.onclive.com/web-exclusives/FDA-Approves-Frontline-Panitumumab-for-KRAS-Wild-type-mCRChttp://www.onclive.com/web-exclusives/FDA-Approves-Frontline-Panitumumab-for-KRAS-Wild-type-mCRChttp://www.cancer.gov/cancertopics/druginfo/fda-cetuximabhttp://www.cancer.gov/cancertopics/druginfo/fda-cetuximabhttp://www.cancer.gov/cancertopics/druginfo/fda-cetuximabhttp://www.cancer.gov/cancertopics/druginfo/fda-cetuximabhttp://www.cancer.gov/cancertopics/druginfo/fda-cetuximabhttp://www.cancer.gov/cancertopics/druginfo/fda-cetuximabhttp://www.cancer.gov/cancertopics/druginfo/fda-vemurafenibhttp://www.cancer.gov/cancertopics/druginfo/fda-vemurafenibhttp://www.cancer.gov/cancertopics/druginfo/fda-vemurafenibhttp://www.cancer.gov/cancertopics/druginfo/fda-vemurafenibhttp://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/

  • 9 YEARS

    To develop this drug 9 WEEKS

    To relapse

    www.proteomics.com 5

    The lack of sustained durability of our most precious

    personalised medicines is costly to the drug manufacturer,

    the health service, the physician and the patient

    Wagle et al. 2011. J Clin Oncology 29, 3085-3096

    Personalised Medicine

    http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/

  • Angiogenesis

    Has the closure of one or two stations on the Tube ever stopped you from getting around?

    www.proteomics.com 6

    http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/

  • Chan & Hughes Feb 2015. Transl Lung Cancer Res 2015;4(1):36-54

    www.proteomics.com 7

    NSCLC oncogenic driver mutation landscape

    2015

    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367711/pdf/tlcr-04-01-036.pdfhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367711/pdf/tlcr-04-01-036.pdfhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367711/pdf/tlcr-04-01-036.pdfhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367711/pdf/tlcr-04-01-036.pdfhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367711/pdf/tlcr-04-01-036.pdfhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367711/pdf/tlcr-04-01-036.pdfhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367711/pdf/tlcr-04-01-036.pdfhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367711/pdf/tlcr-04-01-036.pdfhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367711/pdf/tlcr-04-01-036.pdfhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367711/pdf/tlcr-04-01-036.pdfhttp://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/

  • Canonical disease pathway analysis

    Canonical PD Markers

    www.proteomics.com 8

    http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/http://www.proteomics.com/

  • Comprehensive disease pathway analysis

    Canonical PD Markers

    Alternate PD Markers

    Alternate PD Markers

    www.proteomics.co

View more >